AKARI THERAPEUTICS PLC

AKTX stock slides 18% below its 200‑day average, low liquidity, no revenue yet—investors warned to watch for a sharp correction or breakthrough partnership.

Akari Therapeutics’ stock drops 12.8% while peers stay flat; investors eye Q1 2027 trials, strategic U.S. partnerships, and cost discipline for a potential turnaround.

Akari Therapeutics (AKTX) soars 20.9% in a single day—why? Explore the micro‑cap rally’s drivers, volatility risks, and what it means for investors.

Akari Therapeutics surged 20.9% on 21 May 2026, reflecting strong clinical momentum. Investors eye its anti‑inflammatory pipeline and U.S./UK market expansion for future growth.